Effects of the Japanese Herbal Medicine “Sho-saiko-to”
(TJ-9) on Interleukin-12 Production in Patients with
HCV-Positive Liver Cirrhosis by Yamashiki, Masayoshi et al.
Developmental Immunology, 1999, Vol. 7(1), pp. 17-22
Reprints available directly from the publisher
Photocopying permitted by license only
(C) 1999 OPA (Overseas Publishers Association)
N.V. Published by license under the
Harwood Academic Publishers imprint,
part of Gordon and Breach Publishing Group
Printed in Malaysia
Effects of the Japanese Herbal Medicine "Sho-saiko-to"
(TJ-9) on Interleukin-12 Production in Patients with
HC-Positive Liver Cirrhosis
MASAYOSHI YAMASHIKIab*, AKIRA NISHIMURAc, XIAN-XI HUANGa, TSUTOMU NOBORIa,
SEIGO SAKAGUCHId and HIROYUKI SUZUKIb
aDepartment ofLaboratory Medicine, Mie University School ofMedicine, Tsu, Mie, Japan, bDivision of Gastroenterology, University of
Maryland, Baltimore, Maryland, CDivision ofInternal Medicine, Suzuka General Hospital, Suzuka, Mie, Japan and dDepartment of Gastro-
enterology, Fukuoka University Chikushi Hospital, Chikushino, Fukuoka, Japan
(Revised 21 May, 1998; Infinalform 05 August, 1998)
Interleukin-12 (IL-12) is an important cytokine for maintainence of normal systemic defense
and bioregulation. The Japanese herbal medicine Sho-saiko-to (TJ-9) has been administered
to 1.5 million Japanese patients with chronic liver diseases. TJ-9 is known to significantly
suppress cancer development in the liver and has macrobiotic effects. In the present study, we
examined the in vitro production of IL-12 by circulating mononuclear cells from liver cirrho-
sis patients and the effects of TJ-9 on IL-12 production.
The monocyte/macrophage fraction and the lymphocyte fraction of peripheral blood were
obtained from 11 HCV-positive liver cirrhosis patients and 12 healthy subjects. Interleukin-12
levels in the supernatants were measured using ELISA kits. The levels of IL-12 produced by
the patients’ fractions were significantly lower than those produced by healthy subjects (p <
0.01, p < 0.05). However, when TJ-9 was added to the cultures, the IL-12 production levels in
both cell fractions increased approximately three fold, and the levels from the monocyte/mac-
rophage fraction were almost the same as those from healthy subjects. This effect of TJ-9 was
attributable to two of its seven herb components, that is, scutellaria root and glycyrrhiza root.
One possible mechanism for the macrobiotic effects of TJ-9 on liver cirrhosis patients may be
the improvement in IL-12 production.
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INTRODUCTION
Interleukin-12 (IL-12) is known as the natural killer
cell stimulating factor (Kobayashi et al., 1989), and
its stimulatory effects are reported to be 100 to 1000
times more potent than that of IFN-c and IL-2 (Rob-
ertson et al., 1992; Chehimi et al., 1993b). The clini-
cal application of IL-12 to cancer and
immunodeficiency disease has been considered,
because in vitro IL-12 improves the decreased
cell-mediated immune responses and NK cell activity
in patients with HIV infection (Chehimi et al., 1993a,
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1994; Clerici et al., 1993), and when administered to
mice transplanted tumors disappear (Brunda et al.,
1994). Recently, we reported that IL-12 production
capacity of circulating monocyte/macrophages corre-
lated with prognosis of chronic hepatitis C patients
(Yamashiki et al., 1997a).
Herbal medicines, which have been used in China
for several thousand years, are increasingly being
used among practioners of Western medicine in
Japan. In particular, Sho-saiko-to (TJ-9;
Xiao-Chai-Hu-Tang in Chinese), which has been used
for pyretic diseases in China, has been officially
approved in Japan as a medicine for hospital use with
standard quality and quantity of each component, and
it has now been prescribed to approximately 1.5 mil-
lion patients with chronic viral liver diseases. There
have been many Japanese studies on its clinical use-
fulness (Oka et al., 1984; Fujiwara et al., 1987; Tajiri
et al., 1990) TJ-9 is well known to gradually improve
the subjective symptoms and abnormal liver function
of patients with chronic viral liver diseases. Recently,
TJ-9 was reported to induce apoptosis in vitro of
hepatocellular carcinoma cell lines (Yano et al.,
1994), and a 5-year-olSservation of viral liver cirrhosis
patients treated with or without TJ-9 demonstrated
that TJ-9 significantly suppressed liver cancer devel-
opment, and had macrobiotic effects (Oka et al.,
1995). These findings elicited considerable responses,
from researchers. Some Japanese studies reported that
TJ-9 enhances NK activities (Mizoguchi et al., 1986),
and we have also demonstrated that TJ-9 induces var-
ious cytokines (Yamashiki et al., 1994, 1996, 1997b).
Nowadays, TJ-9 has come to be considered as a bio-
logical response modifier.
Considering the importance of IL-12 in cancer
and immunodeficiency diseases, the present study
investigated the effects of TJ-9 on IL-12 production
in the adherent cell (monocyte/macrophage) fraction
and in the non adhered cell (lymphocyte) fraction of
peripheral blood mononuclear cells (MNC) that
were obtained from liver cirrhosis patients and
healthy subjects. In addition, it compared the IL-12
production indices for each of the seven herb com-
ponents of TJ-9.
RESULTS
Interleukin 12 production in the
Monocyte/Macrophage Fraction
In the Me fraction, IL-12 production levels were
decreased in the patient group compared to healthy
subjects: that is, in cultures with medium only, IL-12
production was 256 +_ 54 pg/ml (mean + SE) in
patients, and 650 + 139 pg/ml in a healthy subjects (p
< 0.05, Table I). After SEB induction, IL-12 produc-
tion levels were 1146 __
181 pg/ml in patients and
2773 + 491 pg/ml in a healthy subjects (p < 0.01). On
the other hand, with TJ-9 in the cultures, the produc-
tion levels in the both groups were increased to
approximately three fold, that is, 765 + 130 pg/ml in
patients and 2183 _
223 pg/ml in a healthy subjects.
Interleukin 12 Production in the Lymphocyte
Fraction
In the lymphocyte fraction, the IL-12 production lev-
els in patients tended to be lower than in a healthy
subjects, and after SEB induction, these levels were
310 + 57 pg/ml in patients and 720 + 132 pg/ml in
healthy subjects (p < 0.05). With TJ-9, the production
increased by three times or more in the patients, and
by six times or more in the healthy subjects.
Comparison of Seven Herb Components
In the comparison of the production index when a
herb component, TJ-9, or SEB, was added to the Me
or lymphocyte fraction of healthy subjects, high
scores were obtained for the scutellaria root (index
score: 5.9), glycyrrhiza root (3.7), and bupleurum root
(2.6) in the Me fraction (Table II), and in the lympho-
cyte fraction, high scores were obtained for
scutellaria root (9.4) and glycyrrhiza root (4.4). The
index scores for the remaining five herb components
were lower than 1.7.TJ-9 EFFECTS IL-12 PRODUCTION IN LIVER CIRRHOSIS 19
TABLE Interleukin 12 Production Levels in Patients with
HCV-Positive Liver Cirrhosis
Reagents Controls Patients p-value
In the Monocyte/Macrophage Fraction
Medium 650 139 256 + 54 0.0191
SEB 2773 +/- 491 1146 + 181 0.0077
LPS 1413 _
260 886 286 0.1863
TJ-9 2183 225 765 130 0.0004
In the Lymphocyte Fraction
Medium 36.5 +/- 5.7 31.3 +/- 4.5 0.5082
SEB 720 +/- 132 310 +/- 57 0.0125
Con A 226 +/- 31 181 48 0.4372
TJ-9 225 +/- 59 97 +/- 10 0.0546
Mean +/- SE (pg/ml).
Controls: normal healthy subjects (n 12).
Patients: HCV-positive liver cirrosis patients (n 11).
p-value: obtained by unpaired t-test.
Medium: no stimulants.
SEB: staphylococcal enterotoxin B.
LPS: lipopolysaccharide.
TJ-9: Japanese herbal medicine "Sho-saiko-to".
Con A: concanavalin A.
TABLE II Interleukin 12 production index for each of Seven Herb
Components
Reagent Production Index
In the Monocyte In the Lymphocyte
/ Fraction Fraction
Bupleurum root 2.64 +/- 0.37 1.66 + 0.31
Pinellia tuber 1.46 +/- 0.15 1.48 +/- 0.16
Scutellaria root 5.88 +/- 1.01 9.42 +/- 1.49
Jujubefruit 1.74 +/- 0.33 1.36 + 0.16
Ginseng root 1.40 +/- 0.18 0.98 +/- 0.05
Glycyrrhiza root 3.74 +/- 0.77 4.42 + 1.46
Ginger rhizome 1.54 +/- 0.29 1.02 + 0.04
TJ-9 5.13 +/- 1.03 6.45 +/- 1.41
SEB 4.75 +/- 0.70 23.70 +/- 5.60
Production index (production level when a test substance was
added to a culture) (production level when only medium
control was added to a culture).
Mean +/- SE.
: macrophage.
TJ-9: Japanese herbal medicine "Sho-saiko-to".
SEB: staphylococcal enterotoxin B.
DISCUSSION
This in vitro study demonstrated that IL-12 produc-
tion levels in both the Me and lymphocyte fractions
of the liver cirrhosis patients were significantly lower
than those in the healthy subjects, and TJ-9 increased
IL-12 production in both cell fractions of the patients
to a level almost the same as those of healthy subjects.
Interleukin 12 is produced by macrophages and B
lymphocytes rather than T lymphocytes. The B/T
ratio was higher in liver cirrhosis patients than in the
healthy subjects (data not shown). Therefore, this
suggests IL-12 production capacities of macrophage
and B lymphocytes are impaired in liver cirrhosis
patients. We consider that induction of IL-12 in
chronic hepatitis C patients could be quite important
to obtain a better therapeutic outcome (Yamashiki et
al., 1997a).
The usual daily dose of TJ-9 is 7.5 g, and this con-
tains 4.5 g of dried extract obtained from bupleurum
root, 7 g; pinellia tuber, 5 g; scutellaria root, 3 g;
jujube fruit, 3 g; ginseng root, 3 g; glycyrrhiza root, 2
g; and ginger rhizome, 1 g. In the comparison of the
production indexes, we used each herb component at
the same concentration. We found that IL-12 was
induced mainly by the scutellaria root and then by the
glycyrrhiza root. These findings were similar to those
found for the induction of TNF-c (Yamashiki et al,
1996). The major chemical content of scutellaria root
is bicalin and that of glycyrrhiza root is glycyrrhizin.
However, in an examination using these chemical
compounds, no induction of IL-12 was observed (data
not shown). Therefore, the IL-12 induction observed
for the two herb components might be attributable to
unknown chemical components.
TJ-9 strongly induces the production of various
cytokines, in particular, IL- 1, IL- 10, tumor necrosis
factor alpha (TNF-(x), and granulocyte colony-stimu-
lating factor (G-CSF), by peripheral mononuclear
cells (Yamashiki et al., 1994, 1996, 1997b). These
effects are similar to those of LPS. To confirm that the
observed in vitro TJ-9 effects were not induced by the
mixed LPS into the TJ-9 bulk powder (which contains
0.00067% of LPS), we also examined IL-12 produc-
tion by using reagents that were treated with taxol (an20 MASAYOSHI YAMASHIKI et al.
LPS antagonist; Wako Pure Chemical Industries,
Osaka). As a result, LPS-induced IL-12 production in
the Me fraction decreased by approximately 1/2 to
1/6 with taxol treatment, but IL-12 production
induced by TJ-9 was not affected by taxol treatment.
Therefore, we consider that increased IL-12 produc-
tion in cultures with TJ-9 is not the result of mixed
LPS in the culture but is specific to TJ-9. In addition,
because the highest serum concentration of TJ-9 after
1 week of administration is presumed to be 200 to
300 tg/ml (Yano et al., 1994). the final concentration
of TJ-9 used in this study (100 tg/ml) would be practi-
cal.
It is impossible to demonstrate the in vivo IL-12
induction by TJ-9 in patients with liver cirrhosis
because the IL-12 level in the circulating blood is
lower than minimum level measurable and also
because the possibility of macrophages being acti-
vated and producing IL-12 without adhering to tissues
is low. It would be worthwhile to investigate the
changes in IL-12 producing cells of the organs such as
the liver, spleen, lung, and lympho nodes from
patients with liver cirrhosis, together with the expres-
sion of IL-12 messenger RNA in these organ tissues,
and their changes after TJ-9 treatment.
Some of the advantages of herbal medicines are
that their side effects are much milder than chemically
produced drugs, and the herb moderately modifies the
biological defense mechanism. However, at the same
time, their moderate effects are a disadvantage: their
efficacy in a short period of time is rather difficult to
confirm, and many physicians, not only in Europe or
the United States, but also in Japan, have doubted the
efficacy of herbal medicines. In Japan, there have
been 66 cases reported of interstitial pneumonia dur-
ing TJ-9 treatment, mainly in hepatitis C patients.
Although this incidence is quite low (far less than
0.01%) in the entire patients who received TJ-9
(approximately 1.5 million persons), 9 patients have
died. This unfortunate event, however, also happens
to indirectly suggest the effects of TJ-9 on the immu-
noregulation system.
Liver cancer is thought to occur within 10 years in
50% of viral liver cirrhosis patients. Induction of
IL-12 may be useful to prevent cancer development,
and IL-12 induction by TJ-9 could be an explanation
for the macrobiotic effects of TJ-9 observed in the
5-year study of liver cirrhosis patients (Oka et al,
1995) In addition, because TJ-9 suppresses HIV pro-
liferation in vitro, it may also be useful in the treat-
ment of malignant diseases or immunodeficient
diseases, including HIV infections (Buimovici-Klein
et al., 1990). Through the clarification of the true
immunological effects of herbal medicines, physi-
cians may be able to obtain a novel and highly useful
biological modifier, and herbal medicines could be an
efficacious remedy for immune-related diseases as
well as infectious diseases.
MATERIALS AND METHODS
Patients and Controls
Peripheral blood was collected from 11 liver cirrhosis
patients and 12 healthy volunteers (university stu-
dents or employees). They understood the purpose of
this study, and consent was given for the blood sam-
pling and its use in this study. The 11 patients were
hepatitis C virus (HCV)-positive. The ages and sexes
of the patients and the controls were roughly similar.
Cell Preparation
As Jdescribed in our previous studies (Yamashiki et
al., 1994, 1996, 1997a, 1997b), heparinized periph-
eral venous blood was collected, and the mononuclear
cell (MNC) fraction was obtained using the lympho-
cyte separation solution (Muto Pure Chemicals,
Tokyo). The MNC fraction was washed 3 times with
Roswell Park Memorial Institute (RPMI) medium
1640 (Gibco Laboratories, Grand Island, NY), and
suspended at a density of 1 x 106cells/ml in the RPMI
culture medium supplemented with 10% heat-inacti-
vated fetal bovine serum (FBS, Gibco Laboratories)
and two antibiotics (Flow laboratories, Irvine, Scot-
land), that is, penicillin 50 IU/ml (final concentration)
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experiments except for washing, we used this MNC
suspended RPMI medium (MNC suspension).
To obtain cell fractions, the wells of 24-well culture
plates (Becton Dickinson Labware, Lincoln Park, NJ)
were coated with heat-inactivated human serum type
AB, then ml of the MNC suspension was poured
into the wells, and incubated in 5% CO2 -in-air for 60
min at 37C. The non adhered cells were obtained as
the lymphocyte fraction. The adhered cells were
washed twice with RPMI-1640. These cells were then
detached with 0.02% ethylenediamine tetraacetic acid
(EDTA) solution in 0.85% saline (Flow Laboratories),
and used as the Me fraction. Cell surface markers
were examined using a flow cytometer (FACScan,
Beckton Dickinson, San Jose, CA), and CD14-posi-
tive cells were found to be 1% or less in the lympho-
cyte fraction, and 90% or more in the Me fraction.
gation. The final concentration of the drugs and
reagents were as follows: 100 gg/ml for TJ-9 and the
seven herb components; 5 gg/ml for SEB and conA;
and 5 ng/ml for LPS.
Cytokine Level
Interleukin 12 levels in the supernatant were mea-
sured using ELISA kits (T Cell Diagnostics, Woburn,
MA). The IL-12 production with each of the seven
herb components was examined using the Me and
lymphocyte fractions obtained from five healthy sub-
jects. The results were expressed in terms of the pro-
duction index, which was defined as the level of
IL-12 produced in the presence of a drug or reagent
divided by the level produced with culture medium
alone.
Reagents
The bulk powder of TJ-9 and its seven herb compo-
nents were supplied by Tsumura & Co. (Tokyo). Each
drug was dissolved into distilled water by gently
shaking the tube for 2 h at 37C, and then centrifug-
ing twice to remove precipitates. The solution was
passed through a filter unit (Millipore Products Divi-
sion, Bedford, MA) for sterilization, and then diluted
to the final concentration (100 gg/ml) with the
RPMI-1640 solution supplemented with the antibiot-
ics. Stimulants used in this study were staphylococcal
enterotoxin B (SEB, Wako Pure Chemical Industries,
Osaka), concanavalin A (conA, Sigma Chemical, St.
Louis) and lipopolysaccharide (LPS, Sigma).
Cell Culture
The Me suspension was adjusted to 1.5 x 105 cells
/ml and the lymphocyte suspension to 8.5 x 105
cells/ml with the previously mentioned culture
medium. To each well of a 24-well culture plate, 980
gl of either suspension and 20 g of a single test sub-
stance or RPMI-1640 medium was added. The plate
was cultured with 5% CO2-in-air at 37C for 48 h,
and then the supernatants were collected by centrifu-
Statistical Analysis
Statistical analyses on the differences of production
levels between the healthy subjects and liver cirrhosis
patients were carried out using non paired t-test (Stu-
dent’s t-test and Welch’s t-test).
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